^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H4-targeted antibody-drug conjugate

    Related drugs:
    1d
    HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=468, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • mocertatug rezetecan (GSK5733584)
    1d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline
    New P3 trial • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    2d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01) (clinicaltrials.gov)
    P3, N=600, Not yet recruiting, GlaxoSmithKline
    New P3 trial
    |
    paclitaxel • doxorubicin hydrochloride • mocertatug rezetecan (GSK5733584)
    20d
    Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=308, Recruiting, BeOne Medicines | N=227 --> 308
    Enrollment change • First-in-human
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    2ms
    BLUESTAR: A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies (clinicaltrials.gov)
    P1/2, N=370, Recruiting, AstraZeneca | Trial completion date: Mar 2027 --> Sep 2027 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    puxitatug samrotecan (AZD8205) • saruparib (AZD5305) • rilvegostomig (AZD2936)
    3ms
    BEHOLD-2: A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=392, Recruiting, GlaxoSmithKline | Trial primary completion date: Sep 2027 --> Dec 2027
    Trial primary completion date
    |
    mocertatug rezetecan (GSK5733584)
    3ms
    Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    puxitatug samrotecan (AZD8205)
    4ms
    Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) (clinicaltrials.gov)
    P3, N=700, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • doxorubicin hydrochloride • puxitatug samrotecan (AZD8205)
    6ms
    Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    paclitaxel • doxorubicin hydrochloride • puxitatug samrotecan (AZD8205)
    6ms
    BEHOLD-1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=385, Recruiting, GlaxoSmithKline | N=240 --> 385 | Trial primary completion date: Oct 2026 --> Feb 2027
    Enrollment change • Trial primary completion date
    |
    mocertatug rezetecan (GSK5733584)
    6ms
    SGNB7H4V-001: A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=246, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2025 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns
    Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • felmetatug vedotin (PF-08046048)
    8ms
    SGNB7H4V-001: A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=236, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | N=572 --> 236 | Trial completion date: Nov 2027 --> Dec 2025 | Trial primary completion date: Nov 2027 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • felmetatug vedotin (PF-08046048)